Table 1 CKD-3 patient baseline characteristics classified by the development or not of renal anemia
Total | Non-anemic patients n = 242 | Anemic patients n = 102 | Statistical significance | ||
|---|---|---|---|---|---|
Gender | Female [n (%)] | 122 (30.1%) | 93 (30.7%) | 29 (28.4%) | 0.976 |
Age (years) | Median (range) | 67 (22–78) | 68 (22–78) | 65 (24–78) | 0.115 |
Time from CKD diagnosis (years) | Mean (SD) | 4.1 (4.8) | 3.9 (4.8) | 4.7 (4.9) | 0.119 |
Smoking [n, (%)] | Smokers | 41 (10.1%) | 28 (9.2%) | 13 (12.7%) | 0.427 |
Ex-smokers | 158 (39.0%) | 116 (38.3%) | 42 (41.2%) | ||
BMI (Kg/m 2 ) | Mean (SD) | 28.0 (4.1) | 27.9 (3.9) | 28.5 (4.6) | 0.260 |
Blood pressure (mmHg) | Systolic [mean (SD)] | 134.3 (16.0) | 133.8 (15.7) | 135.7 (16.8) | 0.302 |
Diastolic [mean (SD)] | 76.3 (10.2) | 75.6 (9.8) | 78.5 (10.8) | 0.013 | |
MDRD-eGFR (mL/min) | Mean (SD) | 39.1 (9.1) | 40.1 (9.3) | 35.9 (7.9) | 0.000 |
uProtein (g/24 h) | Mean (SD) | 0.7 (1.1) | 0.6 (0.9) | 1.0 (1.4) | 0.011 |
Serum Albumin (g/dL) | Mean (SD) | 4.3 (0.4) | 4.1 (0.4) | 4.3 (0.3) | <0.001 |
Corrected Calcium (mEq/L) | Mean (SD) | 9.4 (0.5) | 9.4 (0.5) | 9.5 (0.43) | 0.005 |
Phosphate (mg/dl) | Mean (SD) | 3.4 (0.7) | 3.4 (0.7) | 3.7 (0.6) | 0.000 |
PTH (pg/ml) | Mean (SD) | 95.9 (63.8) | 91.9 (50.3) | 107.4 (92.0) | 0.181 |
CRP (mg/dl) | Mean (SD) | 2.1 (3.0) | 2.2 (3.0) | 1.7 (2.9) | 0.143 |
Ferritin (ng/dl) | Mean (SD) | 131.8 (0.6) | 128.9 (93.4) | 139.6 (104.9) | 0.365 |
Transferrin saturation index (%) | Mean (SD) | 30.2 (31.1) | 31.4 (35.9) | 26.9 (8.0) | 0.278 |
Folic acid (ng/mL) | Mean (SD) | 8.7 (3.6) | 8.6 (3.6) | 9.0 (3.7) | 0.434 |
Vitamin B12 (pg/mL) | Mean (SD) | 501.6(196.2) | 495.1 (197.5) | 518.9 (193.1) | 0.347 |
Hb (g/dl) | Mean (SD) | 14.2 (1.7) | 14.0 (1.3) | 13.7 (2.5) | 0.000 |
Medications | Antihypertensives [n (%)] | 378 (93.3%) | 278 (91.7%) | 100 (98.0%) | 0.028 |
Anticoagulant / antiplatetet [n (%)] | 31 (7.7%) | 27 (8.9%) | 4 (3.9%) | 0.101 | |
Glucose lowering agents [n (%)] | 117 (28.9%) | 88 (29.0%) | 29 (28.4%) | 0.906 | |
Lipid lowering agents [n (%)] | 242 (59.8%) | 180 (59.4%) | 62 (60.8%) | 0.806 | |
Mineral bone treatment [n (%)] | 41 (10.1%) | 30 (9.9%) | 11 (10.8%) | 0.798 | |
Others [n (%)] | 154 (39.5%) | 120 (41.2%) | 34 (34.3%) | 0.225 |